General Electric's Biopharma Unit Sale Looks Like a Win-Win

In This Article:

Anyone who has been paying much attention to the situation at GE (NYSE: GE) over the past few years is aware that the conglomerate is in slim-down mode. CEO Larry Culp has been selling off non-core assets and trying to turn it into a much more focused organization. The latest big move in that transformation: Culp has sold a large chunk of his new company to his old one, Danaher.

In this segment from MarketFoolery, host Chris Hill and Motley Fool Chief Investment Officer Andy Cross consider the reasons why Wall Street is applauding the deal -- not least of which is that it gives GE a nice chunk of change to pay down its debt. On the other side of the equation, serial acquirer Danaher gets a solid biopharma business to add to its thriving life sciences family, and if it's paying a premium, analysts appear to think it's worth it. They also talk broadly about large acquisitions as a strategy, versus smaller, so-called "tuck-in" acquisitions.

A full transcript follows the video.

More From The Motley Fool

This video was recorded on Feb. 25, 2019.

Chris Hill: Shares of General Electric up 10% this morning. I know! I'm incredulous to say that out loud! GE is selling its biopharma business to Danaher for $21 billion and change. Probably not a surprise that the stock would be up. GE says they're going to use the money to get their balance sheet in order, reduce their leverage. This seems like the obvious smart thing to do.

Andy Cross: Yeah, they have to do that. A little more surprising is that Danaher's stock is up about 8% as well, too, Chris, as we're talking here. Clearly investors see this as a good sign for both companies. Danaher is a serially acquisitive company. It's local here in D.C. They've been enormously successful in rolling up operations over the years and building a life-sciences-focused business. They're going to take this on from GE as GE tries to separate its biotech businesses from its other operations and, like you said, get its balance sheet in order and bring a little life back into that business.

For Danaher investors, you're getting a pretty solid business. They're going to pay a premium for this. They're going to pay a nice penny for it at 17X operating profits, but be able to now put it into a family that has real experience in managing life sciences operations. Good move that investors are seeing across the board.